AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
AnaCardio AB logo
AnaCardio ABPrivate
1 asset: 1 Ph 2AC01Phase 2 · Heart FailureWeak signal30 Jul 2028AC01 · Phase 2————
Angel Pharmaceuticals logo
Angel PharmaceuticalsPrivate
2 assets: 1 Ph 3, 1 Ph 1soquelitinibPhase 3 · Peripheral T-Cell LymphomaWeak signal30 Dec 2026soquelitinib · Phase 1————
A
Angelini Pharma S.p.A. (A.C.R.A.F. S.p.A.)Private
2 assets: 2 approvedApproved assets only31 Jan 2027Cenobamate · Phase 2————
A
Anhui HygeianCells BioMedicalPrivate
1 asset: 1 Ph 1Anhui HygeianCells EE001Phase 1 · Heart FailureWeak signalNone on record————
Ankyra Therapeutics, Inc. logo
Ankyra Therapeutics, Inc.Private
1 asset: 1 Ph 1Tolododekin AlfaPhase 1 · Non-Small Cell Lung CancerApr 2027Tolododekin Alfa · Phase 1————
Antag Therapeutics logo
Antag TherapeuticsPrivate
1 asset: 1 Ph 2AT-7687Phase 2 · ObesityFeb 2027AT-7687 · Phase 2————
Anwita Biosciences, Inc. logo
Anwita Biosciences, Inc.Private
1 asset: 1 Ph 1AWT020Phase 1 · Non-Small Cell Lung Cancer30 Apr 2028AWT020 · Phase 1————
AOBiome logo
AOBiomePrivate
1 asset: 1 Ph 2Nitrosomonas eutropha (B244)Phase 2 · Atopic DermatitisReliable signalNone on record————
A
AOP Orphan Pharmaceuticals GmbHPrivate
1 asset: 1 approvedApproved assets only18 Nov 2027Ropeginterferon alfa-2b (Besremi) · Phase 3————
Apellis Pharmaceuticals logo
Apellis PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyJul 2027Pegcetacoplan · Phase 3————
Aplagon logo
AplagonPrivate
1 asset: 1 Ph 2APACPhase 2 · Atherosclerotic Cardiovascular Disease30 Jun 2027APAC · Phase 2————
Apogee Therapeutics logo
Apogee TherapeuticsPrivate
3 assets: 1 Ph 2, 2 Ph 1ZumilokibartPhase 2 · Atopic DermatitisNov 2026Zumilokibart · Phase 2—$972MJun 2026~16.4 qtrs$226M
Apollo Therapeutics logo
Apollo TherapeuticsPrivate
4 assets: 3 Ph 2, 1 Ph 1camoteskimabPhase 2 · Atopic DermatitisPartial signalJul 2027APL-4098 · Phase 1————
A
Apotex Inc.Private
5 assets: 5 approvedApproved assets onlyNone on record————
Appello Pharmaceuticals, Inc. logo
Appello Pharmaceuticals, Inc.Private
1 asset: 1 Ph 2AP-472Phase 2 · Parkinson's Disease3 Sep 2027AP-472 · Phase 2————
APRINOIA Therapeutics logo
APRINOIA TherapeuticsPrivate
1 asset: 1 Ph 1APNmAb005Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
Araclon Biotech (Grifols) logo
Araclon Biotech (Grifols)Private
1 asset: 1 Ph 2ABvac40Phase 2 · Alzheimer's DiseasePartial signalNone on record————
A
Aralez Pharmaceuticals Canada Inc.Private
1 asset: 1 approvedApproved assets onlyNone on record————
ARCA Biopharma (Genvara Biopharma) logo
ARCA Biopharma (Genvara Biopharma)Private
1 asset: 1 Ph 2BucindololPhase 2 · Heart FailurePartial signalNone on record————
ARCE Therapeutics, Inc. logo
ARCE Therapeutics, Inc.Private
1 asset: 1 Ph 2ARD103Phase 1/2 · Acute Myeloid LeukemiaOct 2028ARD103 · Phase 1/2————
Arcera Life Sciences logo
Arcera Life SciencesPrivate
1 asset: 1 Ph 3EnavogliflozinPhase 3 · Type 2 DiabetesReliable signalNov 2027Enavogliflozin · Phase 3————
Areteia Therapeutics logo
Areteia TherapeuticsPrivate
1 asset: 1 Ph 2dexpramipexolePhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signalNone on record————
AriBio logo
AriBioPrivate
1 asset: 1 Ph 3AR1001Phase 3 · Alzheimer's DiseasePartial signalNone on record————
Arog Pharmaceuticals, Inc. logo
Arog Pharmaceuticals, Inc.Private
1 asset: 1 Ph 3CrenolanibPhase 3 · Acute Myeloid LeukemiaReliable signalNone on record————
Aromics Therapeutics logo
Aromics TherapeuticsPrivate
1 asset: 1 Ph 1AROG4-01Phase 1 · Non-Small Cell Lung CancerNone on record————
Aronora logo
AronoraPrivate
2 assets: 2 Ph 2AB002Phase 2 · Chronic Kidney DiseasePartial signalNone on record————
A
Artax BiopharmaPrivate
1 asset: 1 Ph 2AX-158Phase 1/2 · PsoriasisNone on record————
Artery Therapeutics logo
Artery TherapeuticsPrivate
1 asset: 1 Ph 1CS6253Phase 1 · Alzheimer's DiseasePartial signalNone on record————
Asher Biotherapeutics, Inc. logo
Asher Biotherapeutics, Inc.Private
1 asset: 1 Ph 1Etakafusp alfaPhase 1 · Non-Small Cell Lung CancerWeak signalNone on record————
A
Ashibio IncPrivate
1 asset: 1 Ph 3AndecaliximabPhase 2/3 · Fibrodysplasia Ossificans ProgressivaDec 2028Andecaliximab · Phase 1/2————
AskBio logo
AskBioPrivate
1 asset: 1 Ph 2Ametefgene parvecPhase 2 · Parkinson's DiseaseWeak signal30 Apr 2028Ametefgene parvec · Phase 2————
Aspen Neuroscience logo
Aspen NeurosciencePrivate
1 asset: 1 Ph 1SasineprocelPhase 1 · Parkinson's Disease30 Mar 2027Sasineprocel · Phase 1————
A
Astex Pharmaceuticals, Inc.Private
1 asset: 1 approvedApproved assets only1 Nov 2027Capivasertib · Phase 3————
AtaiBeckley Inc. logo
AtaiBeckley Inc.Private
3 assets: 3 Ph 2BPL-003 (mebufotenin benzoate)Phase 2 · Major Depressive DisorderPartial signalNone on record—$169MJun 2026~5.2 qtrs$76M
Atavistik Bio, Inc. logo
Atavistik Bio, Inc.Private
1 asset: 1 Ph 1ATV-1601Phase 1 · HR+/HER2- Metastatic Breast CancerDec 2027ATV-1601 · Phase 1/2————
Athos Therapeutics logo
Athos TherapeuticsPrivate
1 asset: 1 Ph 2ATH-063Phase 2 · Ulcerative ColitisWeak signal14 Dec 2028ATH-063 · Phase 2————
Atom Therapeutics logo
Atom TherapeuticsPrivate
2 assets: 2 Ph 2ABP-745Phase 2 · Atherosclerotic Cardiovascular Disease31 Oct 2027Lingdolinurad · Phase 2————
Aulos Bioscience, Inc. logo
Aulos Bioscience, Inc.Private
1 asset: 1 Ph 2ImneskibartPhase 1/2 · Non-Small Cell Lung Cancer28 Feb 2027Imneskibart · Phase 1/2————
A
Auricula Biosciences Inc.Private
1 asset: 1 Ph 2WEF-001Phase 1/2 · Non-Small Cell Lung CancerJan 2028WEF-001 · Phase 1/2————
Aurigene Discovery Technologies Limited logo
Aurigene Discovery Technologies LimitedPrivate
2 assets: 1 Ph 2, 1 Ph 1EmavusertibPhase 2 · Acute Myeloid LeukemiaJan 2027AUR107 · Phase 1————
Auron Therapeutics, Inc. logo
Auron Therapeutics, Inc.Private
1 asset: 1 Ph 1AUTX-703Phase 1 · Acute Myeloid LeukemiaApr 2027AUTX-703 · Phase 1————
AusperBio logo
AusperBioPrivate
1 asset: 1 Ph 2AHB-171Phase 2 · Chronic Hepatitis B8 Oct 2027AHB-171 · Phase 1————
Autobahn Therapeutics logo
Autobahn TherapeuticsPrivate
1 asset: 1 Ph 2ElunetiromPhase 2 · Major Depressive DisorderNone on record————
Avanzanite Bioscience logo
Avanzanite BiosciencePrivate
1 asset: 1 approvedApproved assets onlyMar 2029Mitapivat · Phase 3————
AvenCell Europe GmbH logo
AvenCell Europe GmbHPrivate
1 asset: 1 Ph 1Allo-RevCAR01-TPhase 1 · Acute Myeloid LeukemiaMay 2027Allo-RevCAR01-T · Phase 1————
Avenzo Therapeutics, Inc. logo
Avenzo Therapeutics, Inc.Private
3 assets: 3 Ph 2AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer31 Jan 2028AVZO-021 · Phase 1/2————
Avere Therapeutics logo
Avere TherapeuticsPrivate
1 asset: 1 Ph 2HS-20118Phase 2 · Psoriasis25 Dec 2026HS-20118 · Phase 1————
Avistone Biotechnology logo
Avistone BiotechnologyPrivate
3 assets: 2 Ph 3, 1 Ph 2VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signalNov 2026Andamertinib · Phase 2————
Avobis Bio logo
Avobis BioPrivate
1 asset: 1 Ph 2AVB-114Phase 2 · Crohn's DiseasePartial signalNone on record————
Axon Neuroscience logo
Axon NeurosciencePrivate
1 asset: 1 Ph 2AADvac1Phase 2 · Alzheimer's DiseaseWeak signalNone on record————
Ayrmid Ltd. logo
Ayrmid Ltd.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Azurity Pharmaceuticals logo
Azurity PharmaceuticalsPrivate
10 assets: 10 approvedApproved assets onlySep 2027Zonisamide (Zonisade) · Approved————
Bambusa Therapeutics logo
Bambusa TherapeuticsPrivate
2 assets: 1 Ph 2, 1 Ph 1BBT002Phase 1/2 · Chronic Obstructive Pulmonary Disease31 Dec 2026BBT002 · Phase 1————
Base Therapeutics (Shanghai) Co., Ltd. logo
Base Therapeutics (Shanghai) Co., Ltd.Private
2 assets: 2 Ph 1NK520Phase 1 · Acute Myeloid LeukemiaWeak signalJun 2027NK510 · Phase 1————
B
BCWorld PharmPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Beeline Medicines logo
Beeline MedicinesPrivate
3 assets: 2 Ph 2, 1 Ph 1LomedeucitinibPhase 2 · PsoriasisPartial signalApr 2030Afimetoran · Phase 2/3————
B
Beijing Bio-Targeting Therapeutics TechnologyPrivate
1 asset: 1 Ph 2BioTTT001Phase 1/2 · Non-Small Cell Lung Cancer31 Jul 2027BioTTT001 · Phase 1/2————
B
Beijing BiotechPrivate
5 assets: 5 Ph 2Beijing Biotech anti-CD19 CAR-TPhase 1/2 · Systemic Lupus Erythematosus14 Feb 2027Dual-target Car-nk Cells · Phase 1/2————
B
Beijing Dongfang BiotechPrivate
1 asset: 1 Ph 3exendin-4 Fc fusion (JY09)Phase 3 · Type 2 DiabetesNone on record————
B
Beijing Greatway PharmaceuticalPrivate
1 asset: 1 Ph 2GW117Phase 2 · Major Depressive DisorderPartial signalNone on record————
Beijing Immunochina Medical Science & Technology Co., Ltd. logo
Beijing Immunochina Medical Science & Technology Co., Ltd.Private
3 assets: 3 Ph 1IM21 CAR-T cellsPhase 1 · Multiple MyelomaWeak signalNone on record————
Beijing Inno Medicine logo
Beijing Inno MedicinePrivate
1 asset: 1 Ph 2YN001Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal31 Jul 2027YN001 · Phase 2————
Beijing Joekai Biotechnology logo
Beijing Joekai BiotechnologyPrivate
1 asset: 1 Ph 250561Phase 2 · Alzheimer's DiseasePartial signalNone on record————
Beijing Mabworks Biotech Co., Ltd. logo
Beijing Mabworks Biotech Co., Ltd.Private
2 assets: 1 Ph 3, 1 Ph 2Obinutuzumab beta (Bejescin)Phase 3 · Systemic Lupus ErythematosusDec 2027MBS314 · Phase 1/2————
B
Beijing Northland BiotechPrivate
1 asset: 1 Ph 3NL003Phase 3 · Atherosclerotic Cardiovascular DiseaseNone on record—$17MSep 2025Ended Aug 2026$6.1M
Beijing QL Biopharmaceutical logo
Beijing QL BiopharmaceuticalPrivate
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1zovaglutidePhase 3 · ObesityReliable signal3 Dec 2026zovaglutide · Phase 1————
Beijing Wehand-Bio Pharmaceutical logo
Beijing Wehand-Bio PharmaceuticalPrivate
1 asset: 1 Ph 1mulberry twig alkaloidsPhase 1 · ObesityWeak signalNone on record————
B
Beijing Xinkanghe Biomedical Technology Co., Ltd.Private
1 asset: 1 Ph 3LecankitugPhase 3 · PsoriasisNone on record————
B
Belenos BiosciencesPrivate
1 asset: 1 Ph 2CM512Phase 2 · Atopic DermatitisWeak signal21 Jul 2027CM512 · Phase 2————
Benethera Biotechnology logo
Benethera BiotechnologyPrivate
1 asset: 1 Ph 1BDHK-2009Phase 1 · Ulcerative ColitisNone on record————
Beta Pharma, Inc. logo
Beta Pharma, Inc.Private
2 assets: 1 Ph 3, 1 Ph 2RezivertinibPhase 3 · Non-Small Cell Lung CancerReliable signalNone on record————
BeyondBio logo
BeyondBioPrivate
1 asset: 1 Ph 2BEY2153Phase 2 · Alzheimer's DiseasePartial signalJul 2028BEY2153 · Phase 2————
BIAL - Portela logo
BIAL - PortelaPrivate
3 assets: 2 approved, 1 Ph 2ZamicastatPhase 2 · Pulmonary Arterial HypertensionWeak signalNone on record————
Biocad logo
BiocadPrivate
8 assets: 7 Ph 3, 1 Ph 1AcellbiaPhase 3 · Rheumatoid ArthritisReliable signalJul 2028Torutamig · Phase 3————
BioCity Biopharmaceutics logo
BioCity BiopharmaceuticsPrivate
1 asset: 1 Ph 3SC0062Phase 3 · Chronic Kidney Disease31 Dec 2026SC0062 · Phase 3————
Biocodex logo
BiocodexPrivate
1 asset: 1 approvedApproved assets onlyAug 2030Stiripentol · Phase 3————
Biocon Biologics logo
Biocon BiologicsPrivate
3 assets: 2 approved, 1 Ph 1Bmab1700Phase 116 Aug 2027Bmab1700 · Phase 1————
BioEclipse Therapeutics logo
BioEclipse TherapeuticsPrivate
1 asset: 1 Ph 1CRX100Phase 1 · Non-Small Cell Lung CancerNone on record————
B
Bioeq AGPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
BioGenCell logo
BioGenCellPrivate
1 asset: 1 Ph 2BGC101Phase 1/2 · Atherosclerotic Cardiovascular DiseaseNone on record————
Biogenea Pharmaceuticals Ltd. logo
Biogenea Pharmaceuticals Ltd.Private
1 asset: 1 Ph 1Microlyvaq™Phase 1 · Non-Small Cell Lung Cancer2 Feb 2028Microlyvaq™ · Phase 1————
BioLite logo
BioLitePrivate
1 asset: 1 Ph 2PDC-1421Phase 2 · Major Depressive DisorderPartial signal28 Feb 2028PDC-1421 · Phase 1/2————
B
Biolitec PharmaPrivate
1 asset: 1 otherAflibercept (Eyluxvi)Age-Related Macular DegenerationNone on record————
Biomed Industries logo
Biomed IndustriesPrivate
1 asset: 1 Ph 2NA-931Phase 2 · ObesityPartial signal15 Aug 2027NA-931 · Phase 2————
Bionyra Pharma logo
Bionyra PharmaPrivate
1 asset: 1 Ph 1TL-003Phase 1 · Ulcerative ColitisApr 2027TL-003 · Phase 1————
B
BiopeuticsPrivate
1 asset: 1 Ph 3alprostadilPhase 3 · Heart FailureNov 2029alprostadil · Phase 3————
B
BioprojetPrivate
1 asset: 1 approvedApproved assets onlyApr 2027Pitolisant (Wakix) · Phase 3————
BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.) logo
BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.)Private
2 assets: 2 otherBCMA-CART (Bioray Laboratories)Multiple Myeloma15 Mar 2027BRL-305 · Phase na————
Biosion logo
BiosionPrivate
2 assets: 1 Ph 2, 1 otherBosakitugPhase 2 · Atopic DermatitisWeak signalNone on record————
Biotest AG logo
Biotest AGPrivate
1 asset: 1 Ph 3Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3None on record————
BioTheryX, Inc. logo
BioTheryX, Inc.Private
1 asset: 1 Ph 1BTX-9341Phase 1 · HR+/HER2- Metastatic Breast Cancer30 Sep 2027BTX-9341 · Phase 1————
Biotroy Therapeutics logo
Biotroy TherapeuticsPrivate
1 asset: 1 Ph 2BT02Phase 1/2 · Non-Small Cell Lung CancerMar 2027BT02 · Phase 1————
Bluefin Biomedicine logo
Bluefin BiomedicinePrivate
1 asset: 1 Ph 3BFB759Phase 2/3 · Hidradenitis Suppurativa28 Feb 2027BFB759 · Phase 2————
Blueprint Medicines logo
Blueprint MedicinesPrivate
2 assets: 1 approved, 1 Ph 2BLU-924Phase 1/2 · Non-Small Cell Lung Cancer30 Jul 2027Pralsetinib · Approved————
BlueRock Therapeutics logo
BlueRock TherapeuticsPrivate
1 asset: 1 Ph 3Bemdaneprocel (MSK-DA01)Phase 3 · Parkinson's DiseaseWeak signalOct 2028Bemdaneprocel (MSK-DA01) · Phase 3————
BlueSphere Bio logo
BlueSphere BioPrivate
2 assets: 1 Ph 2, 1 Ph 1BSB-1001Phase 1/2 · Acute Myeloid LeukemiaNone on record————
BnH Research (Korea) logo
BnH Research (Korea)Private
1 asset: 1 Ph 1BnH-015BPhase 1 · Alzheimer's DiseaseNone on record————
Boehringer Ingelheim logo
Boehringer IngelheimPrivate
39 assets: 17 approved, 9 Ph 3, 8 Ph 2, 4 Ph 1, 1 otherPramipexoleUS approval withdrawn · Parkinson's DiseasePartial signal8 Dec 2026survodutide · Phase 1————
B
Boston OncologyPrivate
2 assets: 2 Ph 3BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signalNone on record————
Brexogen logo
BrexogenPrivate
1 asset: 1 Ph 1BxC-I17ePhase 1 · Atopic DermatitisNone on record————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415